English | Spanish
ecancer
Supporting oncology professionals through education
Login Register

The content on this site is intended for healthcare professionals only

  • Home
  • News
  • Journal
  • Video
  • elearning
  • Events
  • Conferences
  • About us
Breast Prostate & urology Lung & pleura Colorectal & gastro Melanoma & skin Head & neck Ovary & gynaecology Bone Brain & nervous system Haematology oncology Hepatobiliary pancreatic Paediatric Neuroendocrine Sarcomas

News

  • Latest news
  • Sign up for news alerts
  • Submit your news

Explore

  • Bone
  • Brain & nervous system
  • Breast
  • Colorectal & gastro
  • Haematology oncology
  • Head & neck
  • Hepatobiliary pancreatic
  • Lung & pleura
  • Melanoma & skin
  • Neuroendocrine
  • Ovary & gynaecology
  • Paediatric
  • Prostate & urology
  • Sarcomas

Journal information

  • Journal home
  • Charges
  • Editorial board
  • Founding editors
  • Editor-in-chief
  • Contact us

Author information

  • Submit article
  • Author guidelines
  • Editorial policies
  • Copyright information
  • Why publish with us

Reviewer information

  • Reviewer guidelines

Memberships

Open Access Scholarly Publishers Association Crossref Healthcare Information For All Commitee On Publication Ethics

Videos

  • Recent videos
  • Sign up

Explore

  • Bone
  • Brain & nervous system
  • Breast
  • Colorectal & gastro
  • Haematology oncology
  • Head & neck
  • Hepatobiliary pancreatic
  • Lung & pleura
  • Melanoma & skin
  • Neuroendocrine
  • Ovary & gynaecology
  • Paediatric
  • Prostate & urology
  • Sarcomas

Conferences

  • Latest conferences
  • Sign up for latest coverage
  • Submit your event

About ecancer

  • About ecancer
  • Our founders
  • Funding statement
  • Contact us
  • Home
  • News
  • Journal
  • Video
  • elearning
  • Events
  • Conferences
  • About us
Breast Prostate & urology Lung & pleura Colorectal & gastro Melanoma & skin Head & neck Ovary & gynaecology
+ -
Bone Brain & nervous system Haematology oncology Hepatobiliary pancreatic Paediatric Neuroendocrine Sarcomas

ecancer and the City Cancer Challenge have formed an educational collaboration. Learners who are part of the City Cancer Challenge's project can access additional education provided by them.

Please login or register. Then you can use this button to confirm you are part of this project.
Register for free Already have an account? Login
Videos [1803]
News [2707]
Articles [198]
Editorials [1]
Conferences [135]
elearning [13]
Trial supports radiotherapy and cisplatin should remain the standard of care for p16+ oropharyngeal cancer
Trial supports radiotherapy and cisplatin should remain the standard of care for p16+ oropharyngeal cancer
Study confirms fibrosis as a prognostic indicator in the most common breast cancer, and opens the way to antifibrotic drug treatments
Study confirms fibrosis as a prognostic indicator in the most common breast cancer, and opens the way to...
ESMO 2024: Neoadjuvant TAR-200 plus cetrelimab nearly doubles the pathological complete response rate compared to cetrelimab alone in patients with muscle-invasive bladder cancer
ESMO 2024: Neoadjuvant TAR-200 plus cetrelimab nearly doubles the pathological complete response rate compared to...
Novel triplet regimen yields promising response in advanced-phase chronic myeloid leukaemia
Novel triplet regimen yields promising response in advanced-phase chronic myeloid leukaemia
FDA approves pembrolizumab with chemotherapy for unresectable advanced or metastatic malignant pleural mesothelioma
FDA approves pembrolizumab with chemotherapy for unresectable advanced or metastatic malignant pleural mesothelioma
ESMO 2024: Survival benefits from adding perioperative durvalumab to chemo in MIBC
ESMO 2024: Survival benefits from adding perioperative durvalumab to chemo in MIBC
ESMO 2024: Novel ADC AZD8205 demonstrates manageable safety profile and preliminary efficacy in first-in-human trial
ESMO 2024: Novel ADC AZD8205 demonstrates manageable safety profile and preliminary efficacy in first-in-human...
ESMO 2024: Trastuzumab deruxtecan effective against brain mets in HER2-positive breast cancer
ESMO 2024: Trastuzumab deruxtecan effective against brain mets in HER2-positive breast cancer
Researcher develops drug delivery system for chemo-induced hearing loss
Researcher develops drug delivery system for chemo-induced hearing loss
University develops novel bone cancer therapy which has 99% success rate
University develops novel bone cancer therapy which has 99% success rate
<1...910111213...271>

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation

  • Contact
  • Projects
  • Cookie Policy
  • Terms of Use
  • Desktop Site
  • Privacy Policy
© 2025 ecancer, all rights reserved
UK registered charity number: 1176307
Back to Top